dna疫苗
纳米载体
卵清蛋白
癌症疫苗
抗原
化学
生物
免疫
免疫系统
细胞生物学
免疫学
免疫疗法
药物输送
有机化学
作者
Mio Maeta,Naoya Miura,Hiroki Tanaka,Takashi Nakamura,Ryo Kawanishi,Yoshifumi Nishikawa,Kenichi Asano,Masato Tanaka,Shinya Tamagawa,Y. Nakai,Kota Tange,Hiroki Yoshioka,Hideyoshi Harashima,Hidetaka Akita
标识
DOI:10.1021/acs.molpharmaceut.9b01262
摘要
DNA vaccinations are promising strategies for treating diseases that require cellular immunity (i.e., cancer and protozoan infection). Here, we report on the use of a liposomal nanocarrier (lipid nanoparticles (LNPs)) composed of an SS-cleavable and pH-activated lipidlike material (ssPalm) as an in vivo DNA vaccine. After subcutaneous administration, the LNPs containing an ssPalmE, an ssPalm with vitamin E scaffolds, elicited a higher gene expression activity in comparison with the other LNPs composed of the ssPalms with different hydrophobic scaffolds. Immunization with the ssPalmE-LNPs encapsulating plasmid DNA that encodes ovalbumin (OVA, a model tumor antigen) or profilin (TgPF, a potent antigen of Toxoplasma gondii) induced substantial antitumor or antiprotozoan effects, respectively. Flow cytometry analysis of the cells that had taken up the LNPs in draining lymph nodes (dLNs) showed that the ssPalmE-LNPs were largely taken up by macrophages and a small number of dendritic cells. We found that the transient deletion of CD169+ macrophages, a subpopulation of macrophages that play a key role in cancer immunity, unexpectedly enhanced the activity of the DNA vaccine. These data suggest that the ssPalmE-LNPs are effective DNA vaccine carriers, and a strategy for avoiding their being trapped by CD169+ macrophages will be a promising approach for developing next-generation DNA vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI